Related Experiment Video
Updated: Sep 22, 2025
08:49
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
11.3K
PLSec: A novel, liquid biomarker for HCC risk
Joseph W Franses1, Irun Bhan2, Andrew X Zhu3
1Massachusetts General Hospital Division of Hematology-Oncology, Harvard Medical School, Boston, MA 02114, USA.
Med (New York, N.Y.)
|May 19, 2022
Summary
Researchers developed a blood test to predict hepatocellular carcinoma (HCC) risk in cirrhosis patients. This tool utilizes gene signatures and computational analysis for improved accuracy in identifying individuals at high risk for liver cancer.
Area of Science:
- Hepatology
- Genomics
- Bioinformatics
Background:
- Cirrhosis significantly increases the risk of developing hepatocellular carcinoma (HCC).
- Predicting individual HCC risk in cirrhosis patients remains challenging due to ill-defined contributing factors.
Purpose of the Study:
- To develop a robust, blood-based predictor for hepatocellular carcinoma (HCC) risk.
- To identify individuals with cirrhosis who are at a higher risk of developing HCC.
Main Methods:
- Utilized hepatic gene signatures for analysis.
- Employed computational analysis to develop the risk predictor.
- Focused on a blood-based approach for streamlined assessment.
Main Results:
- A streamlined and robust blood-based predictor of HCC risk was developed.
- The predictor leverages hepatic gene signatures and computational methods.
- This approach aims to improve risk stratification in cirrhosis patients.
Conclusions:
- The developed blood test offers a promising tool for HCC risk prediction in cirrhosis.
- This method could aid in early detection and management of liver cancer in at-risk populations.
